Clinical trial
Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis…
NCT00161941 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161941 |
|---|---|
| Title | Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216 |
| Official title | Open-label Multicenter Phase 3B Follow-up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens One Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in the NeisVac-C Non-interference Study 216 |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Meningococcal Meninigitis, Serogroup C |
| Enrollment | 321 |
| Start date | Jun 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Sep 13, 2005 |
| Last update posted | May 21, 2015 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: